360 related articles for article (PubMed ID: 29905899)
1. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews.
Ribeiro ELA; de Mendonça Lima T; Vieira MEB; Storpirtis S; Aguiar PM
Eur J Clin Pharmacol; 2018 Oct; 74(10):1215-1233. PubMed ID: 29905899
[TBL] [Abstract][Full Text] [Related]
2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
4. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
Citrome L; Kalsekar I; Baker RA; Hebden T
Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104
[TBL] [Abstract][Full Text] [Related]
5. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
6. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Stip E; Tourjman V
Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
9. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
Kruse G; Wong BJ; Duh MS; Lefebvre P; Lafeuille MH; Fastenau JM
Pharmacoeconomics; 2015 Oct; 33(10):1049-67. PubMed ID: 25963579
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
[TBL] [Abstract][Full Text] [Related]
11. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.
Klemp M; Tvete IF; Skomedal T; Gaasemyr J; Natvig B; Aursnes I
J Clin Psychopharmacol; 2011 Dec; 31(6):698-704. PubMed ID: 22020356
[TBL] [Abstract][Full Text] [Related]
12. Selection of atypical antipsychotics for the management of schizophrenia.
Sprague DA; Loewen PS; Raymond CB
Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
[TBL] [Abstract][Full Text] [Related]
13. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
Maayan L; Correll CU
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T; McCutcheon RA; Vano L; Mizuno Y; Arumuham A; Hindley G; Beck K; Natesan S; Efthimiou O; Cipriani A; Howes OD
Lancet Psychiatry; 2020 Jan; 7(1):64-77. PubMed ID: 31860457
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
Kishi T; Ikuta T; Matsuda Y; Sakuma K; Iwata N
Psychopharmacology (Berl); 2020 May; 237(5):1459-1470. PubMed ID: 32002559
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
[TBL] [Abstract][Full Text] [Related]
17. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
18. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
Maher AR; Maglione M; Bagley S; Suttorp M; Hu JH; Ewing B; Wang Z; Timmer M; Sultzer D; Shekelle PG
JAMA; 2011 Sep; 306(12):1359-69. PubMed ID: 21954480
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
